



MODULE 7

THE REFERRAL PROCESS IN IASSIST

Coordinator Corner has developed this summary to assist your learning and help you fully understand the information featured in this video

Video breakdown by topic

1 Topic: Preparing a submission | Time: 0:11

- As you navigate through iAssist, you'll find that the online steps are familiar. The process is quick and efficient
- Before you begin, prepare by gathering everything you need, including:
 - Patient log
 - Medical information
 - Insurance and pharmacy card information
 - Discharge summary
 - NICU notes
 - Any other documentation that you would typically submit with the referral
- Coordinator quick tip: A simple courtesy call to a parent can help you gather any missing information
- Once you are ready, click the Start Now button on your iAssist dashboard
 - A window will appear allowing you to search for the patient and start the process
 - If you are adding a new patient, simply click Add as New, create a profile, and begin the submission process
 - When searching for a patient, once the patient name appears, click on the profile link to visit his or her profile
 - There you will see a list of medications. Choose one of those medications and you will be sent to the Patient Prescription page
 - You are then prompted to select 1 of 2 service types:
 - Submitting an ePrescription
 - Submitting a prior authorization or reauthorization form

2 Topic: Submit an ePrescription to a specialty pharmacy | Time: 1:25

- This option will be used for a referral being sent to a specialty pharmacy
 - The pharmacy would then get approval from the insurance company to ship the product

Please see Important Safety Information on page 3, and accompanying full Prescribing Information for SYNAGIS® (palivizumab), including Patient Information.



2 Topic: Submit an ePrescription to a specialty pharmacy *(continued)*

- Once you choose Submit ePrescription, you'll be prompted to complete the following forms:
 - Patient prescription
 - Patient authorization
 - Pharmacy selection
 - Medical history
- *Note: you can always save your submission by clicking Save as Draft.*
- Once you've completed the forms, simply review, confirm, and submit

3 Topic: Submit a prior authorization/reauthorization form | Time: 2:03

- Choose this option when a prescription or referral needs to go to the payer or insurance company first
- Most of the steps included in the previous Specialty Pharmacy ePrescription section are applicable to this section
 - The only difference with this option is you will have to complete a prior authorization step
- After each submission for all options, you will also have the ability to:
 - View patient authorizations submitted to the payer
 - Download or preview specialty pharmacy provider forms as well as print confirmations
 - Access everything from your iAssist dashboard, including your recent submissions and any submissions you saved as drafts

If you have any questions, you can find answers through iAssist:



Live, online chat feature offered for your convenience



Support is available by calling 877-450-4412

IMPORTANT SAFETY INFORMATION

Adverse reactions occurring greater than or equal to 10% and at least 1% more frequently than placebo are fever and rash. In post-marketing reports, cases of severe thrombocytopenia (platelet count <50,000/microliter) and injection site reactions have been reported.

Please see additional Important Safety Information on page 3, and accompanying full Prescribing Information for SYNAGIS® (palivizumab), including Patient Information.

IMPORTANT SAFETY INFORMATION (continued)

- SYNAGIS is contraindicated in children who have had a previous significant hypersensitivity reaction to SYNAGIS
- Cases of anaphylaxis and anaphylactic shock, including fatal cases, have been reported following initial exposure or re-exposure to SYNAGIS. Other acute hypersensitivity reactions, which may be severe, have also been reported on initial exposure or re-exposure to SYNAGIS. The relationship between these reactions and the development of antibodies to SYNAGIS is unknown. If a significant hypersensitivity reaction occurs with SYNAGIS, its use should be permanently discontinued. If a mild hypersensitivity reaction occurs, clinical judgment should be used regarding cautious readministration of SYNAGIS
- As with any intramuscular injection, SYNAGIS should be given with caution to children with thrombocytopenia or any coagulation disorder
- Palivizumab may interfere with immunological-based RSV diagnostic tests, such as some antigen detection-based assays
- Adverse reactions occurring greater than or equal to 10% and at least 1% more frequently than placebo are fever and rash. In post-marketing reports, cases of severe thrombocytopenia (platelet count <50,000/microliter) and injection site reactions have been reported

INDICATION

SYNAGIS is indicated for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) in pediatric patients:

- with a history of premature birth (≤ 35 weeks gestational age) and who are 6 months of age or younger at the beginning of RSV season
- with bronchopulmonary dysplasia (BPD) that required medical treatment within the previous 6 months and who are 24 months of age or younger at the beginning of RSV season
- with hemodynamically significant congenital heart disease (CHD) and who are 24 months of age or younger at the beginning of RSV season

LIMITATIONS OF USE

The safety and efficacy of SYNAGIS have not been established for treatment of RSV disease.

DOSING

The recommended dose of SYNAGIS is 15 mg/kg of body weight given monthly by intramuscular injection. The first dose of SYNAGIS should be administered prior to commencement of the RSV season and the remaining doses should be administered monthly throughout the RSV season. Children who develop an RSV infection should continue to receive monthly doses throughout the RSV season.

The efficacy of SYNAGIS at doses less than 15 mg/kg, or of dosing less frequently than monthly throughout the RSV season, has not been established.

Please see accompanying full Prescribing Information for SYNAGIS, including Patient Information.

